Crystallization is a vital step in the development and production of small molecule active pharmaceutical ingredients (APIs), playing a pivotal role in defining the purity, stability and manufacturability of APIs. It has a direct influence on key quality aspects, including purity, polymorphic form, particle size distribution and downstream processability.
Watch this on-demand webinar (held in November 2025) to gain a clear understanding of how early crystallization decisions impact downstream operations, cost, and time-to-market—supported by real-world case studies and practical insights.
The importance of crystallization in API development and manufacturing
Strategies for solid form selection and control
Scale-up challenges and solutions
The role of PAT and QbD in crystallization process design
Case studies from development to commercial scale
Jayadeva Sajankila, VP & Head
VP & Head, Chemical Development Solutions, Aragen
Nilesh C Hastak, SSBB, Associate Director
Particle Science & Engineering, Aragen
